PFE reports today and may have some information on progress to renegotiate EU's multi-year contract to purchase a gazilion shots that no one wants there either. Whatever his shortcomings, Albert Bourla must be one helluva a salesman. Or at least Ursula von der Leyen thinks so.
The quarter, due to contract obligations should be in line. It is the 2023 outlook that is more interesting. Analysts have been walking back estimates and recommendations for the last couple of weeks. Not sure how you model ewwww, yuck but they are finding a way. It is much more preferable to asking about PFE's rapidly deteriorating reputation as calls to remove all mRNA vaccines from the market grow.
The public, of course caught on quite a while ago. The uptake for the bivalent booster is less than 20% They are just waiting for the rest of the world to catch up.
Should be an interesting earnings report.
Have a great day out there.
Emily Evans
Managing Director – Health Policy
Twitter
LinkedIn
